

RESEARCH OPPORTUNITY

NAMI is committed to improving the lives of people impacted by mental health conditions through effective treatments, equitable public policies, and greater knowledge and understanding in society. Research is essential to advance each of these goals. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting research participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these studies.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email research@nami.org.

WHAT IS THE STUDY?

This study is a double-blind randomized clinical trial to evaluate the efficacy and safety of two mobile applications (apps) as an adjunct treatment for individuals with schizophrenia who are experiencing moderate to severe negative symptoms. Negative symptoms can include difficulty with motivation or enjoying daily life. Total participation time is about 22 weeks, including a 2-week screening period, a 16-week treatment period in which participants will use one of the study apps every day, and a 4-week follow up period. Each participant will receive the study app and related support at no cost; reimbursement for participation and travel may be available.

WHO CAN PARTICIPATE?

Participants may be eligible for this study if they:

- Are at least 18 years of age
- Have a primary diagnosis of schizophrenia and are currently experiencing negative symptoms
- Have been on a stable dose of antipsychotic medication for at least 12 weeks before starting the study
- Own a smartphone compatible with Android 10 or greater or iOS 14 or greater
- Have the ability to visit a study center 4 times and have 3 phone calls with the study team throughout the study

The researchers are seeking 432 people for this study.

WHERE IS THE STUDY TAKING PLACE?

This is a multicenter study with sites located in the following states: Arizona, California, Connecticut, Florida, Georgia, Illinois, Mississippi, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, and Texas.

HOW DO I LEARN MORE?

The documents attached have additional information about the study. If you have questions or would like more information, please visit <https://www.convokestudy.com>